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Abstract
There has been the impression amongst many observers that discussion of a grant application has little practical impact
on the final priority scores. Rather the final score is largely dictated by the range of preliminary scores given by the
assigned reviewers. The implication is that the preliminary and final scores are the same and the discussion has little
impact. The purpose of this examination of the peer review process at the National Institutes of Health is to describe the
relationship between preliminary priority scores of the assigned reviewers and the final priority score given by the
scientific review group. This study also describes the practical importance of any differences in priority scores. Priority
scores for a sample of standard (R01) research grant applications were used in this assessment. The results indicate that
the preliminary meeting evaluation is positively correlated with the final meeting outcome but that they are on average
significantly different. The results demonstrate that discussion at the meeting has an important practical impact on over
13% of the applications.
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Introduction
Peer Review at the National Institutes of Health (NIH), a United
States Government agency that supports biomedical research, has
twoseparate stages:theinitialscientificmerit reviewof the proposed
research by a panel of peers; and a second level review by the
Advisory Councils and Boards for funding Institutes and Centers
(ICs). The IC Councils and Boards are composed of scientists from
the extramural research community and public representatives [1].
The IC Councils and Boards evaluate the relevance of the proposed
sciencetothemission of the IC,the potentialimpactof the research,
andtheIC’s concurrence with theinitial review.TheNIHdualpeer
review system is mandated by federal statute [2].
The Center for Scientific Review (CSR) manages the review of
approximately 70% of all applications submitted to NIH in the
first phase of the peer review process. Most of these are standard
research grant applications (R01s). The initial scientific merit
review conducted by CSR is further divided into two serial
segments. The first segment is the assignment of the application to
three or more panel members to prepare the critique and provide
a preliminary or pre-meeting score. The second stage is for the full
panel to review the application and discuss the critiques before
they vote a final priority score for the application. This phase is
usually in the form of a face-to-face meeting
Grant application peer review has been compared to an art
form, combining individual assessments of quality and impact.
There are difficulties in quantifying or validating the final results
[3] and the rating scale has also been challenging [4]. Over the
past 20 years the impression has emerged that discussion of
applications may have little impact on final meeting scores as
reflected by the change in the average of the independently
derived pre-meeting scores and the final score. While many
studies on the CSR peer review process have been published
[e.g. 5, 6, 7, 8], one aspect not examined is the effect of
discussion on final peer review outcomes, a focus of this study. In
addition, this study will consider the practical consequences of
any final priority score change from the average preliminary
score.
The data are broken down by: (A) preliminary individual and
average priority scores: (B) magnitude of differences; (C), the
degree to which the final priority score was outside the minimum
and maximum of the individual assigned reviewer’s preliminary
priority scores; (D), the magnitude of differences as a function of
final priority score and (E) the practical consequences.
Methods
Data were derived from the IMPAC2 Data File maintained by
NIH’s Office of Extramural Research. The data set included R01
(standard research grant) applications reviewed by CSR for the
January 2009 review round. The dataset was a sample of all R01
application reviews.
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investigator indicated involvement of human subjects in the
proposed research by checking ‘‘yes’’ on page 1 of the grant
application form in response to a query about involvement of
human subjects. Excluded from this definition are applications
that identified human subjects in the research and claimed
Exemption 4. Exemption 4 applies to research involving the
collection or study of existing data, documents, records, patho-
logical specimens, or diagnostic specimens, if these sources are
publicly available or if the information is recorded by the
investigator in a manner that subjects cannot be identified,
directly or through identifiers linked to the subjects. This definition
of clinical research captures research on mechanisms of disease,
therapeutic intervention, clinical trials, development of technolo-
gies, epidemiological and behavioral studies and outcomes as well
as health services research.
Study sections that review R01 applications are of two main
types: Standard Review Groups (SRGs) and Special Emphasis
Panels (SEPs). SRGs are panels that have defined charters
describing their areas of scientific expertise. They typically meet
three times a year and are comprised of appointed members who
serve for four years combined with temporary members who serve
once to provide supplemental expertise. The initial peer review
panels meet face-to-face and usually include 20 to 35 reviewers.
This analysis includes only SRG panel data. It does not include
reviews occurring in SEPs since these reviews use many formats
(e.g., face-to face and web-based discussion) that could complicate
the interpretation of results. The small number of R01 applications
reviewed by SEPs also limits the ability to analyze results from
these meetings.
For each application a minimum of three review panel members
are assigned to review the application: at least two provide written
critiques and one may be only a discussant who adds to comments
made by the first two assigned reviewers. All three assigned
reviewers provide independently derived ‘‘preliminary’’ priority
scores using a standardized set of evaluation criteria.
At the beginning of the panel discussion the assigned reviewers
verbally re-state their independent assessments of the appropriate
priority scores for the panel. After the discussion the assigned
reviewers were asked to verbally re-state their priority scores.
These scores may be the same as or different than their pre-
discussion preliminary scores. These scores, which are given after
the discussion, are not captured and thus were not part of this
assessment. These scores would also have been modified by the
discussion and not independent.
If an application was deemed to be ‘‘non-competitive’’ (in the
lower half, quantitatively of applications reviewed by the panel), by
unanimous agreement of the members, it was not discussed at the
meeting and did not receive a final priority score [9]. Because
these applications were not discussed they did not include a final
priority score, and could not be included in this study.
Approximately 50% of the applications go on to further discussion
by the full panel.
The panels used incremental units of 0.1 in scoring applications
from 1.0 (highest merit) to 5.0 (lowest merit). The individual panel
members, including the three assigned reviewers, independently
and privately score the application after the discussion. The
purpose was to preserve confidentially and independence of
personal voting. CSR review panel members were allowed to score
applications up to 0.5 points outside the range stated by the
assigned reviewers’ without indicating to the other members of the
panel they were ‘out of range’. Reviewers were not allowed to vote
outside more than 0.5 outside this range unless they made a
statement to the panel since the score could be due to a substantive
difference of opinion or fact that had not been fully explored
during the discussion.
For the purposes of this study the preliminary score refers to the
average of the three assigned reviewers’ independent scores,
expressed to two decimal places. The final priority score of the
SRG, also reported to two decimal places, is the average score of
all the voting members of the panel (some members may be in
conflict and would not participate in the discussion or vote).
The ICs use the priority scores and a calculated percentile
ranking in assisting in their decisions regarding funding [10].
Using percentile ranking enables ICs to integrate the outcomes of
multiple SRGs. After the SRG meeting each application that
received a final priority score was also assigned a percentile value.
The percentile for an R01 application is its relative rank within
that SRG. The calculated percentile value for a given R01
application specifies the percent of applications with scores equal
to or better than that application, The base used for calculating the
SRG percentile for an application is defined by all R01
applications assigned for review by the SRG over three review
rounds, whether the application was discussed and scored or not.
Because preliminary scores are based on only thee members of the
study section there is no base and thus they are not percentiled.
Therefore a direct comparison of the preliminary evaluation with
the final percentile for the panel is not possible. Thus, comparisons
and analysis were limited to priority scores.
Results
Description of Sample
CSR conducted R01 reviews in 172 SRGs for the January 2009
Council review meeting dates. Of these, 61 SRGs were included in
this sample. The total number of R01 applications reviewed in all
SRGs for the January 2009 Council round was 7,503; approxi-
mately 50% of these were not discussed and thus did not receive a
final priority score [8]. Applications without a preliminary or final
priority score were removed from the analysis. Applications with
average preliminary and final priority scores from 1.00 to 3.00
were included. After removing unscored applications, there were
1,395 scored applications reviewed in the 61 SRGs, or 42% of the
total of all SRG-reviewed and scored R01 applications. SRGs that
participated in this study were randomly selected and represent the
range of science reviewed by CSR.
Average Preliminary versus Final Priority Scores
Figure 1 illustrates the differences between preliminary and final
priority scores for all R01s in the sample that received a final
priority score of 3.00 or better. Examples of extreme movement
include an application with a preliminary score of 2.60 and a final
priority score of 1.43 and another with a preliminary score of 1.70
and a final priority score of 2.90. Most differences between
average preliminary and final priority scores were in a more
narrow range. Overall, the Pearson correlation coefficient is 0.78
(N=1,395).
Differences Between Preliminary and Final Priority Scores
Table 1 shows the results of paired-sample t-tests that were used
to assess whether the means of the preliminary and final scores
were statistically different from each other. Overall, the analyses
show that there were statistically significant differences between
preliminary scores and final scores for all types of R01s at the
p,0.01 level, except for New Investigators. New Investigators
represented the only group where the mean difference between the
preliminary (1.81) and final priority scores (1.82) were not
statistically different.
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PLoS ONE | www.plosone.org 2 November 2010 | Volume 5 | Issue 11 | e13526Magnitude of Differences
When the difference between preliminary and final priority
scores are rank ordered (Figure 2), only 4% of SRG R01
applications had no change (0.00) in priority score, 45% improved
and 51% were worse after discussion. The maximum observed
changes in average preliminary score to final priority score was an
improvement of +1.29 and decline of 21.34.
Range of Reviewer’s Preliminary versus Final Priority
Scores
The assigned reviewer’s scores established the preliminary score
range (e.g., if preliminary scores were 1.2, 1.3 and 1.6, the
preliminary score range would be 1.2 to 1.6 – with 1.2 being the
best and 1.6 being the worst preliminary score). In aggregate,
after discussion, the final priority scores remained within the
preliminary score range 80.2% of the time (Figure 3). The balance,
19.8%, were outside of the preliminary range (either better or
worse). They were better (lower priority score) 7.3% of the time
and worse (higher priority score) 12.5% of the time. Thus,
discussion more often increases than decreases the priority score
(e.g. preliminary score range 1.4 to 1.6 and final score 1.7.
Final Priority Score Percentile ‘‘Range Band’’ and
Magnitude of Change from Preliminary Score
While there is a significant difference between average
preliminary and final priority scores over all, this does mean that
there was a practical significance. The importance of substantial
changes in priority score, where the preliminary and final priority
scores are well beyond any IC funding range, are of lower interest
when it comes to issues such as funding. However, there is the
Figure 1. Average Preliminary Score versus SRG Final Priority Score. Preliminary Scores represent the average of the independent R01
priority scores given by the three assigned reviewers; the final priority score is the average of all the scores given by the voting members of the panel.
Each data point represents the outcome for one R01 application. The difference between preliminary and final priority scores represents the change
between the two values. Applications with differences displayed on the left declined after discussion; those on the right improved.
doi:10.1371/journal.pone.0013526.g001
Table 1. Paired T-Test Comparing Average Preliminary and Final Priority Score.
Application Subgroup N
Preliminary Score
Mean ± SD
Final Score
Mean ± SD Score Difference t-test P-Value
New Investigator 295 1.8160.32 1.8260.27 0.03 20.33 0.37
Experienced Investigator 1,110 1.7560.32 1.7960.04 0.04 26 ,0.01
Clinical Application 422 1.7760.33 1.8360.25 0.06 24.49 ,0.01
Non-Clinical Application 973 1.7560.32 1.7860.24 0.03 23.55 ,0.01
Type 1 Application 865 1.7960.33 1.8360.25 0.04 24.15 ,0.01
Type 2 Application 527 1.7160.30 1.7460.22 0.03 23.39 ,0.01
Overall 1,395 1.7660.32 1.8060.24 0.03 25.26 ,0.01
doi:10.1371/journal.pone.0013526.t001
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PLoS ONE | www.plosone.org 3 November 2010 | Volume 5 | Issue 11 | e13526Figure 2. Effects of SRG Meeting Discussion on Final Priority Score. Applications were rank ordered by the difference between the average
preliminary and final priority score of individual R01 applications and then assigned a cumulative percent value. Applications with negative values are
displayed on the left and improved after discussion; those on the right were worse after discussion.
doi:10.1371/journal.pone.0013526.g002
Figure 3. Range of Reviewer’s Preliminary versus SRGs Final Priority Scores. The average preliminary priority scores of reviewers may all be
the same or represent a range. The final priority score was BETTER, WITHIN or WORSE than this range.
doi:10.1371/journal.pone.0013526.g003
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final priority score is between 1.00 and 1.75. In order to better
understand the practical consequences of the changes in priority
score, applications were sorted into extrapolated percentile ranges
or bands that correspond to estimated percentiles as follows:
1. 1.45: approximated the 12
th percentile,
2. 1.60: approximated the 19
th percentile,
3. 1.75: approximated the 25
th percentile, and
4. 1.76 and above: approximated 26
th percentile and worse
The base for the percentile can be against all the R01s in either
the study section where the application was reviewed (SRG Base)
or against all the R01s reviewed in CSR (CSR ALL base). To
assign a given priority score to a specific percentile, the ‘‘CSR
ALL’’ percentile base was used to estimate these values.
Only 22.6% of R01 applications (Table 2) in the sample had no
or minor movement after discussion (defined as 0.05 or less. Also,
42.6% had changed by 0.15 or more (fourth row). Most of the
applications (29.3%) that had large changes had final priority score
values of 1.75 or worse. Even large changes in this higher range
are unlikely to have a practical impact. As an example of a
potentially important impact on the final percentile score, an
application with an estimated 19
th percentile value (160 priority
score) before the discussion could have had an estimated final
percentile of 12
th percentile (145 priority score) after discussion.
Comparison of Preliminary Score Band with Final Priority
Score
The degree and direction of change from the average
preliminary scores to the final priority scores included some that
got better scores, some that were worse and others that did not
change. Analysis of the magnitude of change from one preliminary
priority score to a final priority score band (columns, Table 3)
provides an indication of the direction and magnitude of change.
Cells in Table 3 noted with a superscript ‘A’, show the percent of
applications with preliminary and final scores that remained in the
same priority score band. Cells noted with a superscript ‘B’ show
the percent of applications with final scores that improved vs. the
preliminary scores. And cells noted with a superscript ‘C’ show the
percent of applications with worse final priority scores than
preliminary scores.
Only 2% of the applications in the 4
th preliminary score band
(1.76 or worse) improved to the 1
st final priority score ‘‘band’’ (1.0
to 1.45); and only 1% in the 1
st preliminary score ‘‘band’’ (1.00 to
1.45), declined to the 4
th final priority score band (1.76 to 3.00).
Priority scores of 1.46 to 1.75 are often assumed by many
reviewers (often erroneously) as the region of the funding pay line
cut-off for ICs. Large changes (0.15 and greater) into or out of the
1.45 to 1.75 range can have substantive practical importance.
Discussion
There is a moderate correlation (0.78) between the average
preliminary and final priority scores for R01 applications reviewed
by CSR/NIH. Since the assigned reviewers are also members of
the review panel and have been selected for their credibility in
peer review and scientific expertise, and that both the panel and
assigned reviewers are using a standard set of review criteria, a
correlation would be expected.
However, this study also establishes that overall the average of
the three preliminary priority scores is significantly different from
the final priority score of the SRG (p=,.01). This also holds true
when the data set is broken down into experienced applicants,
competing renewals (Type 2) or clinical and non-clinical research.
The only exception was for the Type 1 New Principal Investigator
cohort where the scores were not significantly different.
CSR and NIH have had a history of special commitment to
New Principal Investigators [11]. NIH also gives guidance to
reviewers to consider the career stage of the applicant at the time
of review, particularly as it relates to publication history and
preliminary data. One possible explanation for no pre to post
discussion difference could be that both assigned reviewers and
study section members are taking the career stage of New
Principal Investigator applicants into consideration.
Unless the difference between the preliminary and final
priority score leads to an adjustment of such magnitude as to
affect further IC discussion and decisions, the differences are of
little consequence. In this study approximately 13.3% of
applications with priority scores of 1.75 or better have final
priority scores that differ by 0.15 or more from their average
preliminary score. In recent years such changes could be of
considerable importance to ICs, and contribute to their
discussions on funding.
The NIH has recently announced [12] that they have
modified the priority score scale used by reviewers to a single
digit, rather than to a decimal. They have also announced a
revision of the review criteria and the addition of a new class of
applications, the Early Stage Investigators. These modifications
were implemented beginning with the October 2009 review
round. Evaluation of the impact of these modifications on peer
review has just begun.
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Table 2. Magnitude of Change from Preliminary Priority
Score to Final Priority Score by Defined Ranges.
Priority Score Ranges
Magnitude of
Change
1.00–1.45 1.46–1.60 1.61–1.75 1.76 to 3.00 Total
less than .05 6.6% 4.9% 3.7% 7.3% 22.6%
,05 to .099 5.7% 3.1% 3.7% 7.7% 20.2%
.1 to .149 3.9% 2.2% 2.7% 5.9% 14.6%
.15 or more 6.7% 3.2% 3.4% 29.3% 42.6%
Total 22.9% 13.3% 13.5% 50.3% 100.0%
doi:10.1371/journal.pone.0013526.t002
Table 3. Change between Average Preliminary Score and
Final Priority Score.
Final Priority Score
Pre-Meeting Average
Score
1.00–1.45 1.46–1.60 1.61–1.75 1.76–3.00
1.00–1.45 85%
A 11%
c 3%
C 2%
C
1.46–1.60 34%
B 37%
A 16%
C 13%
C
1.61–1.75 9%
B 17%
B 34%
A 40%
C
1.75–3.00 1%
B 3%
B 9%
B 87%
A
doi:10.1371/journal.pone.0013526.t003
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